Large randomised phase III trials conducted in patients with non-small-cell lung cancer (NSCLC) harbouring activating mutations in EGFR have demonstrated that erlotinib or gefitinib are superior to platinum-based chemotherapy.
Related Articles
Impact Factor
Dropping bars or rising hoops phase III outcomes of NSCLC
Senza categoria
Newsround
Senza categoria